Suppr超能文献

腺嘌呤 A 和 A 受体参与了鸟嘌呤对 6-OHDA 诱导的纹状体切片氧化爆发和线粒体功能障碍的保护作用。

Adenosine A and A receptors are involved on guanosine protective effects against oxidative burst and mitochondrial dysfunction induced by 6-OHDA in striatal slices.

机构信息

Programa de Pós-graduação em Bioquímica, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina, Florianópolis, Brazil.

Programa de Pós-graduação em Neurociências, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina, Florianópolis, Brazil.

出版信息

Purinergic Signal. 2021 Jun;17(2):247-254. doi: 10.1007/s11302-021-09765-y. Epub 2021 Feb 6.

Abstract

6-Hydroxydopamine (6-OHDA) is the most used toxin in experimental Parkinson's disease (PD) models. 6-OHDA shows high affinity for the dopamine transporter and once inside the neuron, it accumulates and undergoes non-enzymatic auto-oxidation, promoting reactive oxygen species (ROS) formation and selective damage of catecholaminergic neurons. In this way, our group has established a 6-OHDA in vitro protocol with rat striatal slices as a rapid and effective model for screening of new drugs with protective effects against PD. We have shown that co-incubation with guanosine (GUO, 100 μM) prevented the 6-OHDA-induced damage in striatal slices. As the exact GUO mechanism of action remains unknown, the aim of this study was to investigate if adenosine A (AR) and/or A receptors (AR) are involved on GUO protective effects on striatal slices. Pre-incubation with DPCPX, an AR antagonist prevented guanosine effects on 6-OHDA-induced ROS formation and mitochondrial membrane potential depolarization, while CCPA, an AR agonist, did not alter GUO effects. Regarding AR, the antagonist SCH58261 had similar protective effect as GUO in ROS formation and mitochondrial membrane potential. Additionally, SCH58261 did not affect GUO protective effects. The AR agonist CGS21680, although, completely blocked GUO effects. Finally, the AR antagonist DPCPX, and the AR agonist CGS21680 also abolished the preventive guanosine effect on 6-OHDA-induced ATP levels decrease. These results reinforce previous evidence for a putative interaction of GUO with AR-AR heteromer as its molecular target and clearly indicate a dependence on adenosine receptors modulation to GUO protective effect.

摘要

6-羟多巴胺(6-OHDA)是实验性帕金森病(PD)模型中最常用的毒素。6-OHDA 对多巴胺转运体具有高亲和力,一旦进入神经元,它就会积累并进行非酶自动氧化,促进活性氧(ROS)的形成,并选择性地损伤儿茶酚胺能神经元。通过这种方式,我们的小组建立了一种 6-OHDA 体外大鼠纹状体切片方案,作为一种快速有效的筛选具有 PD 保护作用的新药的模型。我们已经表明,与鸟苷(GUO,100μM)共孵育可防止 6-OHDA 诱导的纹状体切片损伤。由于 GUO 的确切作用机制尚不清楚,本研究的目的是研究是否腺嘌呤 A(AR)和/或 A 受体(AR)参与了 GUO 对纹状体切片的保护作用。AR 拮抗剂 DPCPX 的预孵育可防止 GUO 对 6-OHDA 诱导的 ROS 形成和线粒体膜电位去极化的作用,而 AR 激动剂 CCPA 则不会改变 GUO 的作用。关于 AR,拮抗剂 SCH58261 在 ROS 形成和线粒体膜电位方面与 GUO 具有相似的保护作用。此外,SCH58261 不影响 GUO 的保护作用。AR 激动剂 CGS21680 虽然完全阻断了 GUO 的作用。最后,AR 拮抗剂 DPCPX 和 AR 激动剂 CGS21680 也消除了 GUO 对 6-OHDA 诱导的 ATP 水平降低的预防作用。这些结果进一步证实了 GUO 与 AR-AR 异源三聚体相互作用作为其分子靶点的假设,并明确表明 AR 调节对 GUO 保护作用的依赖性。

相似文献

2
Involvement of adenosine A and A receptors on guanosine-mediated anti-tremor effects in reserpinized mice.
Purinergic Signal. 2020 Sep;16(3):379-387. doi: 10.1007/s11302-020-09716-z. Epub 2020 Jul 28.
3
Guanosine Protects Striatal Slices Against 6-OHDA-Induced Oxidative Damage, Mitochondrial Dysfunction, and ATP Depletion.
Neurotox Res. 2019 Feb;35(2):475-483. doi: 10.1007/s12640-018-9976-1. Epub 2018 Nov 12.
4
Guanosine-Mediated Anxiolytic-Like Effect: Interplay with Adenosine A and A Receptors.
Int J Mol Sci. 2020 Dec 5;21(23):9281. doi: 10.3390/ijms21239281.
8
The antidepressant-like effect of guanosine involves the modulation of adenosine A and A receptors.
Purinergic Signal. 2023 Jun;19(2):387-399. doi: 10.1007/s11302-022-09898-8. Epub 2022 Sep 27.
9
Guanosine prevents depressive-like behaviors in rats following bilateral dorsolateral striatum lesion induced by 6-hydroxydopamine.
Behav Brain Res. 2019 Oct 17;372:112014. doi: 10.1016/j.bbr.2019.112014. Epub 2019 Jun 15.

引用本文的文献

1
Ginsenoside Rg1 in Parkinson's disease: from basic research to clinical applications.
Front Pharmacol. 2025 Apr 16;16:1490480. doi: 10.3389/fphar.2025.1490480. eCollection 2025.
2
Lessons from the physiological role of guanosine in neurodegeneration and cancer: Toward a multimodal mechanism of action?
Purinergic Signal. 2025 Feb;21(1):133-148. doi: 10.1007/s11302-024-10033-y. Epub 2024 Jul 15.
3
Neuroprotection afforded by targeting G protein-coupled receptors in heteromers and by heteromer-selective drugs.
Front Pharmacol. 2023 Jul 13;14:1222158. doi: 10.3389/fphar.2023.1222158. eCollection 2023.
4
Dynamic and Rapid Detection of Guanosine during Ischemia.
ACS Chem Neurosci. 2023 May 3;14(9):1646-1658. doi: 10.1021/acschemneuro.3c00048. Epub 2023 Apr 11.
5
Adenosinergic Pathway in Parkinson's Disease: Recent Advances and Therapeutic Perspective.
Mol Neurobiol. 2023 Jun;60(6):3054-3070. doi: 10.1007/s12035-023-03257-3. Epub 2023 Feb 14.
6
The antidepressant-like effect of guanosine involves the modulation of adenosine A and A receptors.
Purinergic Signal. 2023 Jun;19(2):387-399. doi: 10.1007/s11302-022-09898-8. Epub 2022 Sep 27.

本文引用的文献

1
New Drugs 2020, part 1.
Nursing. 2020 Feb;50(2):31-38. doi: 10.1097/01.NURSE.0000651608.77613.29.
5
Neuromodulatory Effects of Guanine-Based Purines in Health and Disease.
Front Cell Neurosci. 2018 Oct 23;12:376. doi: 10.3389/fncel.2018.00376. eCollection 2018.
6
Guanosine Protects Striatal Slices Against 6-OHDA-Induced Oxidative Damage, Mitochondrial Dysfunction, and ATP Depletion.
Neurotox Res. 2019 Feb;35(2):475-483. doi: 10.1007/s12640-018-9976-1. Epub 2018 Nov 12.
7
Adenosine A-Dopamine D Receptor Heteromers Control the Excitability of the Spinal Motoneuron.
Mol Neurobiol. 2019 Feb;56(2):797-811. doi: 10.1007/s12035-018-1120-y. Epub 2018 May 24.
8
Could istradefylline be a treatment option for postural abnormalities in mid-stage Parkinson's disease?
J Neurol Sci. 2018 Feb 15;385:131-133. doi: 10.1016/j.jns.2017.12.027. Epub 2017 Dec 24.
9
Antiparkinsonian Efficacy of Guanosine in Rodent Models of Movement Disorder.
Front Pharmacol. 2017 Oct 4;8:700. doi: 10.3389/fphar.2017.00700. eCollection 2017.
10
The Efficacy of Istradefylline for Treating Mild Wearing-Off in Parkinson Disease.
Clin Neuropharmacol. 2017 Nov/Dec;40(6):261-263. doi: 10.1097/WNF.0000000000000249.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验